ES2959601T3 - Un polipéptido EphA4 modificado - Google Patents

Un polipéptido EphA4 modificado Download PDF

Info

Publication number
ES2959601T3
ES2959601T3 ES16858502T ES16858502T ES2959601T3 ES 2959601 T3 ES2959601 T3 ES 2959601T3 ES 16858502 T ES16858502 T ES 16858502T ES 16858502 T ES16858502 T ES 16858502T ES 2959601 T3 ES2959601 T3 ES 2959601T3
Authority
ES
Spain
Prior art keywords
epha4
amino acid
protein
sequence
eph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16858502T
Other languages
English (en)
Spanish (es)
Inventor
Perry Bartlett
Andrew Boyd
Mike Gerometta
Leanne Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
QIMR Berghofer Medical Research Institute
Original Assignee
University of Queensland
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904387A external-priority patent/AU2015904387A0/en
Application filed by University of Queensland, Queensland Institute of Medical Research QIMR filed Critical University of Queensland
Application granted granted Critical
Publication of ES2959601T3 publication Critical patent/ES2959601T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES16858502T 2015-10-27 2016-10-27 Un polipéptido EphA4 modificado Active ES2959601T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015904387A AU2015904387A0 (en) 2015-10-27 A method of treatment and agents useful for same
PCT/AU2016/051010 WO2017070738A1 (en) 2015-10-27 2016-10-27 A method of treatment and agents useful for same

Publications (1)

Publication Number Publication Date
ES2959601T3 true ES2959601T3 (es) 2024-02-27

Family

ID=58629613

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16858502T Active ES2959601T3 (es) 2015-10-27 2016-10-27 Un polipéptido EphA4 modificado

Country Status (7)

Country Link
US (1) US10617738B2 (cg-RX-API-DMAC10.html)
EP (1) EP3368551B1 (cg-RX-API-DMAC10.html)
JP (1) JP6877419B2 (cg-RX-API-DMAC10.html)
CN (1) CN108884135B (cg-RX-API-DMAC10.html)
AU (1) AU2016345063B2 (cg-RX-API-DMAC10.html)
ES (1) ES2959601T3 (cg-RX-API-DMAC10.html)
WO (1) WO2017070738A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110702916B (zh) * 2019-04-15 2022-06-21 四川大学华西医院 一种整合蛋白质组和糖蛋白组的定量分析方法
CN117120074A (zh) * 2021-03-18 2023-11-24 V·卡拉斯诺佩洛夫 sEphB4-HSA融合蛋白作为癌症治疗的一线疗法的用途
CN118234864A (zh) * 2021-11-11 2024-06-21 卫材R&D管理有限公司 抗EphA4抗体
WO2023154948A1 (en) * 2022-02-14 2023-08-17 Vasgene Therapeutics Inc. Ephrin type-b receptor 4 (ephb4) agents and production thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DE58906786D1 (de) 1989-11-03 1994-03-03 Siemens Ag Controller-Bussystem für einen programmierbaren, flexiblen Digitalsignal-Multiplexer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
WO1994025503A1 (en) 1993-04-27 1994-11-10 Cytotherapeutics, Inc. Membrane formed by an acrylonitrile-based polymer
AU688776B2 (en) 1993-06-23 1998-03-19 Brown University Research Foundation Method and apparatus for sealing implantable, membrane encapsulation devices
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5840576A (en) 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
WO1996038971A1 (en) 1995-06-01 1996-12-05 Harris Corporation Computer calling method and system
IN181898B (cg-RX-API-DMAC10.html) 1995-06-07 1998-10-24 Cytotherapeutics Inc
WO1997012635A1 (en) 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
EP1730279A2 (en) * 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
US20080003210A1 (en) * 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
EP2166110B1 (en) * 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha4 for gamma-secretase
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
WO2012081502A1 (ja) * 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof

Also Published As

Publication number Publication date
EP3368551B1 (en) 2023-07-12
CN108884135B (zh) 2024-03-26
JP6877419B2 (ja) 2021-05-26
US10617738B2 (en) 2020-04-14
EP3368551A4 (en) 2019-06-05
AU2016345063B2 (en) 2021-08-05
WO2017070738A1 (en) 2017-05-04
AU2016345063A1 (en) 2018-05-17
JP2019501112A (ja) 2019-01-17
AU2016345063A2 (en) 2018-07-19
EP3368551A1 (en) 2018-09-05
US20180339020A1 (en) 2018-11-29
CA3003294A1 (en) 2017-05-04
CN108884135A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
CN109152844B (zh) 用于治疗的含有磺酰胺接头的生物缀合物
AU2004233985A1 (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
BR112019027479A2 (pt) l-asparaginase modificada
US20230399616A1 (en) Modified Red Blood Cells and Uses Thereof for Delivering Agents
US20220073580A1 (en) Il-37 variants
US10617738B2 (en) Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
US20250051410A1 (en) Lilrb polypeptides and uses thereof
CN108570108A (zh) 肿瘤靶向多肽、制备方法及其应用
WO2021247675A1 (en) Coronavirus-binding agents and uses thereof
WO2017193956A1 (zh) 一种双特异性抗原结合构建体及其制备方法和应用
JP2024517855A (ja) 融合ポリペプチド
Zhong et al. Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions
KR102485892B1 (ko) 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
JP2022537052A (ja) 操作された腫瘍選択的タンパク質発現
CA3003294C (en) Modified epha4 and uses thereof
CN116139278B (zh) 一种tim-3棕榈酰化修饰及靶向多肽在肿瘤免疫治疗中的应用
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
IL295624A (en) Molecules targeting proteins
CN114573707A (zh) 一种用于抗肿瘤的新型il-15融合蛋白
WO2003044196A1 (fr) Proteines postsynaptiques
US10287338B2 (en) Factor VIII protein compositions and methods of treating of hemophilia A
WO2004106370A1 (en) M11l derived peptides and therapeutic use thereof
CN117642422A (zh) 用于降低抗体-脂肪酶结合的结构
WO2021257961A1 (en) Compositions and methods for treating cancer